Literature DB >> 7541714

Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

L Rivoltini1, K C Barracchini, V Viggiano, Y Kawakami, A Smith, A Mixon, N P Restifo, S L Topalian, T B Simonis, S A Rosenberg.   

Abstract

MHC class I antigen expression is necessary for CD8+ T-cell-mediated recognition of tumors. Recently, several mechanisms leading to loss or decreased expression of MHC antigens on the tumor cell surface have been described that may account for tumor escape from immune recognition. It is yet unknown whether tumor recognition by CTL occurs at a threshold amount of MHC molecules or correlates with the level of HLA-allele expression. In this study, a model was developed in which clones derived from the 624-MEL melanoma cell line and expressing varying amounts of HLA-A2 molecules were lysed in a standard 51Cr release assay by an HLA-A2-restricted CTL clone (A42) or a bulk culture of tumor-infiltrating lymphocytes. The A42 clone and the tumor-infiltrating lymphocyte culture were characterized previously as specifically recognizing the melanoma antigen MART-1(27-35) peptide. A marked heterogeneity in the susceptibility to lysis by A42 was observed in tumor clones and was not due to heterogeneous expression of MART-1 by the clones or loss of accessory molecules involved in the lymphocyte-target interaction. Lysis by A42 and by the tumor-infiltrating lymphocyte culture significantly correlated with the level of HLA-A2 expression, evaluated as mean channel number of fluorescence by flow cytometry (P < 0.001). Transfection of an HLA-A2-negative clone (624.28) with the HLA-A2.1 gene produced a panel of clones expressing different levels of HLA-A2, the lysis of which was highly correlated with the expression of HLA-A2 (P < 0.001). The addition of exogenous MART-1(27-35) peptide enhanced lysis of clones expressing intermediate amounts of HLA-A2 but did not affect clones with high expression. These data suggest that the number of HLA molecules present on the surface of tumor cells can quantitatively affect their lysis by CTL in situations with borderline amounts of peptide and/or MHC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541714      PMCID: PMC2248458     

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

1.  Cellular peptide composition governed by major histocompatibility complex class I molecules.

Authors:  K Falk; O Rötzschke; H G Rammensee
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

2.  Presentation of viral antigen controlled by a gene in the major histocompatibility complex.

Authors:  V Cerundolo; J Alexander; K Anderson; C Lamb; P Cresswell; A McMichael; F Gotch; A Townsend
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

3.  Limit of T cell tolerance to self proteins by peptide presentation.

Authors:  H Schild; O Rötzschke; H Kalbacher; H G Rammensee
Journal:  Science       Date:  1990-03-30       Impact factor: 47.728

4.  Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma.

Authors:  F Momburg; A Ziegler; J Harpprecht; P Möller; G Moldenhauer; G J Hämmerling
Journal:  J Immunol       Date:  1989-01-01       Impact factor: 5.422

5.  Expression of HLA-A,B,C, beta 2-microglobulin (beta 2m), HLA-DR, -DP, -DQ and of HLA-D-associated invariant chain (Ii) in soft-tissue tumors.

Authors:  G Mechtersheimer; M Staudter; O Majdic; B Dörken; G Moldenhauer; P Möller
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

6.  Selective changes in expression of HLA class I polymorphic determinants in human solid tumors.

Authors:  P G Natali; M R Nicotra; A Bigotti; I Venturo; L Marcenaro; P Giacomini; C Russo
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

8.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.

Authors:  C M D'Urso; Z G Wang; Y Cao; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

9.  ICAM- melanoma cells are relatively resistant to CD3-mediated T-cell lysis.

Authors:  E Braakman; P S Goedegebuure; R J Vreugdenhil; D M Segal; S Shaw; R L Bolhuis
Journal:  Int J Cancer       Date:  1990-09-15       Impact factor: 7.396

10.  Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens.

Authors:  T Wölfel; E Klehmann; C Müller; K H Schütt; K H Meyer zum Büschenfelde; A Knuth
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  40 in total

1.  Functional heterogeneity of vaccine-induced CD8(+) T cells.

Authors:  Vladia Monsurrò; Dirk Nagorsen; Ena Wang; Maurizio Provenzano; Mark E Dudley; Steven A Rosenberg; Francesco M Marincola
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

2.  Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.

Authors:  C J Kim; T Prevette; J Cormier; W Overwijk; M Roden; N P Restifo; S A Rosenberg; F M Marincola
Journal:  J Immunother       Date:  1997-07       Impact factor: 4.456

3.  Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.

Authors:  J N Cormier; M C Panelli; J A Hackett; M P Bettinotti; A Mixon; J Wunderlich; L L Parker; N P Restifo; S Ferrone; F M Marincola
Journal:  Int J Cancer       Date:  1999-03-01       Impact factor: 7.396

4.  MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.

Authors:  Matthias Leisegang; Susanne Wilde; Stefani Spranger; Slavoljub Milosevic; Bernhard Frankenberger; Wolfgang Uckert; Dolores J Schendel
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

5.  Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

Authors:  Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Douglas C Palmer; Luca Gattinoni; Nicholas P Restifo
Journal:  Blood       Date:  2009-06-26       Impact factor: 22.113

6.  HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.

Authors:  David M Woods; Andressa L Sodré; Alejandro Villagra; Amod Sarnaik; Eduardo M Sotomayor; Jeffrey Weber
Journal:  Cancer Immunol Res       Date:  2015-08-21       Impact factor: 11.151

7.  CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Authors:  Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

8.  Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines.

Authors:  Xuede Lin; Xiaojian Wang; Haley L Capek; Laura C Simone; Amit Tuli; Chantey R Morris; Adrian J Reber; Joyce C Solheim
Journal:  Cancer Immunol Immunother       Date:  2008-10-01       Impact factor: 6.968

9.  Increased effector-target cell conjugate formation due to HLA restricted specific antigen recognition.

Authors:  Ching Y Voss; Sara Deola; Thomas A Fleisher; Francesco M Marincola
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

10.  Cystatin E/M suppresses legumain activity and invasion of human melanoma.

Authors:  Jon J Briggs; Mads H Haugen; Harald T Johansen; Adam I Riker; Magnus Abrahamson; Øystein Fodstad; Gunhild M Maelandsmo; Rigmor Solberg
Journal:  BMC Cancer       Date:  2010-01-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.